NCT01907724View on ClinicalTrials.gov

Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Hepatitis C, Chronic
Interventions
DRUG

IDX719

IDX719 will be supplied as a 50 mg tablet for oral administration.

DRUG

Simeprevir

Simeprevir will be supplied as 75 mg capsules for oral administration.

DRUG

TMC647055

TMC647055 will be supplied as 150 mg capsules for oral administration.

DRUG

RTV

RTV will be supplied as 80 mg/mL solution for oral administration.

All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01907724 - Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) | Biotech Hunter | Biotech Hunter